Global Monoclonal Antibodies in Veterinary Health Market Size is valued at USD 0.71 Bn in 2024 and is predicted to reach USD 2.98 Bn by the year 2034 at a 15.7% CAGR during the forecast period for 2025-2034.
Monoclonal antibodies in veterinary health are specialized biologic therapies designed to target specific molecules or pathogens in animals to diagnose, prevent, or treat various diseases. These antibodies offer precise mechanisms of action, improved safety profiles, and targeted treatment options for conditions such as cancer, infectious diseases, inflammatory disorders, and autoimmune diseases in companion animals and livestock. One of the main drivers of the worldwide veterinary monoclonal antibody market is the increasing prevalence of chronic conditions in companion animals, including cancer and atopic dermatitis.
This also highlights the need for deliberate, efficient therapies. Rapid increases in pet adoption and humanization have increased the expense of veterinary care, but increased pet insurance coverage makes expensive biologics more affordable. Moreover, the rapid development of new treatments is enabled by great R&D spending and advancements in antibody engineering technology that enhance product safety and effectiveness. Helpful legislative environments and strategic alliances between biopharma corporations and veterinary organizations also quicken product approvals and market penetration, therefore driving market growth in the next few years.
However, during the forecast period, the high prices of monoclonal antibody treatments, restricted pet insurance coverage, and poor veterinary infrastructure in developing markets could limit target market expansion. Moreover, increased pet adoption rates, increased knowledge of animal diseases, and access to substitute therapies are projected to propel the worldwide market of monoclonal antibodies in the veterinary healthcare sector over the forecast period.
Competitive Landscape
Some Major Key Players In The Monoclonal Antibodies in Veterinary Health Market:
- Boehringer Ingelheim GmbH
- Elanco
- Indian Immunologicals
- Merck
- Virbac
- Zoetis
- adivo GmbH (Part of Zoetis),
- Bayer Animal Health
- Invetx,
- Kindred Biosciences, Inc.
- Other Market Players
Market Segmentation:
The monoclonal antibodies market in veterinary health is segmented by type, application, and end-user. Based on type, the market is segmented into companion animals and livestock. The application segment comprises dermatology, pain, and others. The end-user segment is further divided into veterinary hospitals and others.
Based On The Type, The Companion Animals Segment Accounts For A Major Contributor To Monoclonal Antibodies In The Veterinary Health Market
The companion animal category is expected to hold a major share of the global monoclonal antibodies in the veterinary health market in 2024. This development is due to rising pet ownership and humanization trends, which generate increased healthcare spending. Moreover, fueling the demand for personalized monoclonal antibody treatment is the rising incidence of persistent canine illnesses like cancer and atopic dermatitis. Furthermore, contributing to the strong expansion of this segment are greater pet insurance usage, favourable government regulations, and advances in antibody engineering, which support this therapy's effectiveness and market reach.
The Dermatology Segment Witnessed Growth At A Rapid Rate
The dermatology segment is projected to grow at a rapid rate in the global monoclonal antibodies in the veterinary health market because of the increased prevalence of long-term skin disorders in pets, such as atopic dermatitis. Veterinary professionals and pet owners' growing knowledge and improved diagnostic skills are fueling the need for customized, targeted monoclonal antibody treatments. Furthermore, improvements in antibody engineering are enhancing the safety and effectiveness of treatments, and the development of new products and their commercial acceptance are being sped up by advantageous regulatory environments and strategic industry alliances.
In The Region, The North American Monoclonal Antibodies In The Veterinary Health Market Hold A Significant Revenue Share.
The North American monoclonal antibodies in the veterinary health market are expected to register the largest market revenue share in the near future. This can be because of the rising incidence of chronic diseases in pets; furthermore, increasing pet insurance coverage made expensive biologics more affordable and robust R&D spending, which contributed to the expansion of monoclonal antibodies in veterinary health solutions in the area.
In addition, Asia Pacific is projected to grow at a rapid rate in the global monoclonal antibodies in the veterinary health market as a result of rising local R&D investment in monoclonal antibodies therapies, raising awareness of chronic animal diseases, developing infrastructure, encouraging government programs, and raising disposable incomes that facilitate access to cutting-edge medicines, which is also fueled by the region's growth.
Recent Developments:
- In Oct 2024, Elanco Animal Health presented the inaugural real-world data illustrating the efficacy and impact of their Canine Parvovirus Monoclonal Antibody (CPMA), the sole USDA Conditionally Approved targeted treatment for canine parvovirus.
Monoclonal Antibodies in Veterinary Health Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 0.71 Bn |
|
Revenue Forecast In 2034 |
USD 2.98 Bn |
|
Growth Rate CAGR |
CAGR of 15.7% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application, And End-User. |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Boehringer Ingelheim GmbH, Elanco, Indian Immunologicals, Merck, Virbac, Zoetis, Other Market Players. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
